What is the Purpose of this Study?
Primary Objective: To evaluate the safety and tolerability of BBO-11818 Combination dose escalation only: To determine the recommended dose of BBO-11818 to be administered in combination with: Pembrolizumab +/- [cis/carboplatin + pemetrexed] in subjects with KRASG12D or KRASG12V mutant NSCLC Cetuximab in subjects with KRASG12D or KRASG12V mutant CRC Secondary Objectives: To evaluate preliminary antitumor activity of BBO-11818 monotherapy and in combination with: Pembrolizumab +/- [cis/carboplatin + pemetrexed] in subjects with KRASG12D or KRASG12V mutant NSCLC Cetuximab in subjects with KRASG12D or KRASG12V mutant CRC To characterize the PK of BBO-11818
Eligibility
- * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
- * Measurable disease by RECIST v1.1
- * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute : Marquis Keene, Saba Mukarram
More about this Clinical Trial
What is the full name of this clinical trial?
TBBO11818-101: A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers